Omega-3 PUFA as a basic element of therapy for patients with hypertriglyceridemia

Litvinova S.V., Kochetkov A.I., Sinitsyna I.I., Ostroumova O.D.

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Atherosclerosis-associated cardiovascular diseases (CVD) remain the leading cause of death worldwide. The risk of cardiovascular complications (CVC) remains even if the target level of low-density lipoprotein cholesterol (LDL-C) is achieved. The key factor of residual cardiovascular risk is high triglyceride (TG) levels, the target level of which should not exceed 1.7 mmol/l. To date, omega-3 polyunsaturated fatty acids (PUFAs) are recommended as the main therapy in the treatment of hypertriglyceridemia (HTG). The most studied omega-3 PUFAs are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the use of which can significantly improve the prognosis in patients with a wide range of cardiovascular pathologies.

Keywords

About the Authors

Corresponding author: Olga D. Ostroumova, Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology n.a. Academician M. S. Vovsi, Russian Medical Academy of Continuous Professional Education; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia: ostroumova.olga@mail.ru

Similar Articles